HC Wainwright Analysts Give Sophiris Bio, Inc. (NASDAQ:SPHS) a $6.00 Price Target
Sophiris Bio, Inc. (NASDAQ:SPHS) has been given a $6.00 target price by equities research analysts at HC Wainwright in a research note issued on Friday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s price target points to a potential upside of 210.88% from the company’s previous close.
SPHS has been the subject of a number of other research reports. ValuEngine cut Sophiris Bio from a “hold” rating to a “sell” rating in a research report on Tuesday, June 13th. Maxim Group set a $6.00 price target on Sophiris Bio and gave the stock a “buy” rating in a research report on Tuesday, May 16th. Finally, Rodman & Renshaw reaffirmed a “buy” rating and set a $6.00 price target on shares of Sophiris Bio in a research report on Thursday, June 1st. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $6.60.
Sophiris Bio (NASDAQ:SPHS) opened at 1.93 on Friday. The firm has a 50-day moving average price of $2.08 and a 200-day moving average price of $2.46. The company’s market cap is $58.11 million. Sophiris Bio has a 12-month low of $1.80 and a 12-month high of $6.13.
Sophiris Bio (NASDAQ:SPHS) last issued its quarterly earnings results on Monday, May 15th. The biopharmaceutical company reported ($0.09) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.09). On average, analysts forecast that Sophiris Bio will post ($0.39) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “HC Wainwright Analysts Give Sophiris Bio, Inc. (NASDAQ:SPHS) a $6.00 Price Target” was originally published by Watch List News and is owned by of Watch List News. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this report can be viewed at https://www.watchlistnews.com/hc-wainwright-analysts-give-sophiris-bio-inc-nasdaqsphs-a-6-00-price-target/1471778.html.
Sophiris Bio Company Profile
Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).
Receive News & Ratings for Sophiris Bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.